Decode Health’s Post

Spearheading #multiplesclerosis Breakthroughs: Advanced Diffusion Models In #multiplesclerosis (MS), particularly the relapsing-remitting form, demyelination and inflammation pave the path to neurodegeneration and cognitive decline. Traditional structural MRI, while identifying T2-hyperintense lesions, lacks sensitivity in detecting damage to normal appearing tissues. Enter diffusion-weighted MRI and the duo of diffusion-tensor imaging (DTI) and neurite orientation dispersion and density imaging (NODDI). Active demyelination and inflammation are not confined to focal lesions but extend to NAWM. This systematic review plunges into the heart of the matter, dissecting microstructural abnormalities in lesions and the elusive normal appearing white matter (NAWM) by seamlessly integrating the strengths of both DTI and NODDI. Both methods complement each other, offering a comprehensive view of microstructural changes. Moreover, biomarkers from advanced diffusion models can revolutionize clinical understanding, moving beyond clinical symptoms to assess treatment efficacy and disease progression. Discover More:  https://lnkd.in/exvA76t2 For a Deeper Dive and Collaboration: Reach out to our team at imaging.experts@ia-grp.com About Image Analysis Group (IAG): At the forefront of AI-powered drug development and precision medicine, IAG harnesses the potential of medical imaging and the cutting-edge Dynamika™ platform. We redefine clinical development, offering early drug efficacy assessments, strategic patient recruitment, and predictive analysis. With a pioneering bio-partnering approach, we expand the horizons of asset development through risk-sharing financing and partnering models. #MultipleSclerosis #MSResearch #AdvancedImaging #DTI #NODDI #Breakthroughs #ResearchRevolution #MedicalImaging #clinicalresearch #medicalimaging

Radiomics-derived biomarkers hold great potential but aren't yet common in clinical practice. A recent study by the German Research Foundation tackled this by standardising workflow definitions and identifying key challenges. This effort is crucial for integrating radiomics into clinical settings,and enhancing diagnostics and treatments. Find out more https://iii.hm/1qpc #Radiomics #PersonalizedMedicine #MedicalImaging #HealthcareInnovation

☑️ Abbott has been awarded the CE mark for its insertable cardiac monitor, capable of continuously tracking heart rhythms for up to six years, catering to varying patient needs. ☑️ ProJenX is advancing its ALS treatment after the FDA lifted a partial clinical hold on a phase 1 trial for its drug targeting amyotrophic lateral sclerosis. ☑️ Neuronetics, Inc. has obtained FDA clearance for its depression treatment device for adolescents, a decision William Blair analysts found unexpectedly positive given previous denials in this patient demographic by the FDA. ☑️ Beacon Biosignals has secured the US Food and Drug Administration’s (FDA) 510(k) clearance for SleepStageML, a machine learning software designed to enhance sleep analysis. ☑️ Maverix Medical, a lung cancer startup, has acquired diagnostic developer Cirrus Bio, expanding its capabilities in the lung cancer diagnostic field. ☑️ Metyos secured €2.3 million in funding to advance its wearable kidney disease management device, featuring a bio-wearable sensor and platform for real-time monitoring of chronic kidney disease. Smarteeva's advanced AI technology, combined with experience and expertise is changing the game for medical device companies. Contact us today: https://lnkd.in/gjYE7UEZ #InsightswithSmarteeva #Medtech #complaintmanagement #Pharma #Smarteeva #biotech #medtechtrends #medtechindustry #medicaltechnology #technology #health #medicaldevicediagnostics #ai #mdr #recalls #complaints #mir #fda #cvr

Join Proscia for an insightful panel discussion on the transformative potential of pathology real-world data (RWD). As diagnostic workflows become digitized, each pathology image holds billions of pixels and untapped insights that can accelerate drug discovery and development. Industry experts, including Derek Welch, Ben Freiberg, and Nathan Buchbinder, will share how they are utilizing this data to drive the next breakthroughs in precision medicine. Attendees will gain a clear understanding of how RWD is advancing precision medicine diagnostics and therapies, illustrated through real-world examples and practical use cases. The panel will also provide expert perspectives on the growing impact of RWD as digital pathology adoption continues to rise. Additionally, attendees will develop a deeper appreciation for the critical role clinical laboratories play, not only in delivering today’s precision diagnostics but in shaping the future of novel diagnostics and therapies. Find out more on Pathology News: https://lnkd.in/eX4eaJr5 #digitalpathology #pathologynews

Scopio Labs secures FDA nod for digital bone marrow aspirate application The digital application is designed to run on the company’s X100 and X100HT platforms, to transform the BMA analysis with a new, fully digital workflow. The solution combines high-resolution full-field imaging with an AI-powered decision support system (DSS), to benefit healthcare professionals and patients. It enables hematopathologists to remotely access and review bone marrow smears, reducing turnaround time, and enabling collaboration, expert second opinions, and diagnostic confidence. Scopio Labs CEO Itai Hayut said: “We commend the FDA for acknowledging the essential need to support haematology experts in their complex work. “The approval of the FF-BMA Application arms them with robust decision support systems. “By harnessing AI and Full-Field imaging, labs can streamline workflows, reduce operational costs, and enhance patient care.” Bone marrow cytology refers to the microscopic analysis of cells in bone marrow samples, and is a key diagnostic tool used to identify a wide range of blood disorders. Read more online: https://lnkd.in/eufMEKcm 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #scopiolabs #haematology

𝐅𝐃𝐀 𝐂𝐥𝐞𝐚𝐫𝐬 𝐆𝐫𝐨𝐮𝐧𝐝𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐀𝐈-𝐏𝐨𝐰𝐞𝐫𝐞𝐝 𝐗-𝐑𝐚𝐲 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐋𝐮𝐧𝐠 𝐍𝐨𝐝𝐮𝐥𝐞 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧: The U.S. Food and Drug Administration (FDA) has granted clearance for Qure.ai's qXR-LN, a pioneering X-Ray application utilizing artificial intelligence (AI) for the identification and localization of lung nodules in both plain film and digital medical images. Developed by Qure.ai, this first-of-its-kind technology aims to enhance the identification of potentially malignant pulmonary nodules ranging from 6 to 30 mm in size. Radiologists, pulmonologists, and ER physicians can now leverage this AI-driven solution to advance early detection and diagnosis, potentially improving patient outcomes in lung cancer cases. Mannudeep Kalra, MD, a Massachusetts General Hospital radiologist, emphasizes AI's transformative role in thoracic radiology, foreseeing significant advancements in diagnosis and care facilitated by evolving AI technology. Qure.ai anticipates its software will contribute significantly to early identification and timely interventions in lung cancer cases. #AIHealthcare #digitalmarketing #HealthcareTechnology

According to data, China requires one pathologist for every 100 hospital beds, yet in reality, the country faces a shortage of 90% of pathologist specialists. This shortage significantly impacts the level of care provided to cancer patients. Over the past decade, the establishment and development of 290+ KFBIO digital pathology remote consultation platforms have played a crucial role in addressing this situation. Through KFBIO digital pathology remote consultations, doctors can utilize advanced technology and platforms to overcome geographical limitations and formulate remote diagnostic and treatment plans. This not only increases the utilization of pathology experts but also provides patients with faster and more accurate diagnoses and treatments. Therefore, KFBIO digital pathology remote consultations not only fill the gap in the shortage of pathologists in China but also substantially improve the level of care for cancer patients. #KFBIO #Digitalpathology

Radiomics is an emerging area of medicine that focuses on extracting and analyzing quantitative and qualitative information from medical images, with the aim of improving the diagnosis, prognosis and treatment of diseases. There are several reasons why radiomics is a valuable approach in clinical practice and medical research: 1 - Complementary Information: Medical images, such as computed tomography (CT), magnetic resonance imaging (MRI) and PET-CT, provide a vast amount of information beyond what is perceptible to the naked eye. Radiomics allows complex and subtle features to be extracted from these images, providing additional insights into morphology, texture, vascularization, among other aspects. 2 - Personalizing Treatment: Radiomics can help identify biomarkers and specific tissue characteristics that are associated with different disease phenotypes. This allows for a more personalized approach to treatment, where the therapeutic plan can be adapted based on the patient's individual characteristics. 3 - Prognosis and Treatment Response Prediction: By extracting quantitative information from medical images, radiomics can be used to predict the prognosis of patients and their response to treatment. This can assist doctors in making clinical decisions, helping to identify patients who may benefit from certain therapies or who have a higher risk of disease progression. 4 - Biomarker discovery: Radiomic analysis can lead to the discovery of new non-invasive biomarkers for a variety of diseases. These biomarkers can be useful for early diagnosis, monitoring disease progression and evaluating treatment efficacy. 5 - Clinical Research and Drug Development: In clinical research and drug development, radiomics can be a powerful tool for evaluating the effectiveness of new treatments. It can be used to quantify and characterize changes in medical images over time, allowing for a more objective evaluation of the results of clinical trials. Fortunately, there is python library that can be used: 😉 PyRadiomics: https://lnkd.in/dh56M53y Below is a short video: https://lnkd.in/d-EPV-Vd #radiomics #personalizedmedicine

According to data, China requires one pathologist for every 100 hospital beds, yet in reality, the country faces a shortage of 90% of pathologist specialists. This shortage significantly impacts the level of care provided to cancer patients. Over the past decade, the establishment and development of 290+ KFBIO digital pathology remote consultation platforms have played a crucial role in addressing this situation. Through KFBIO digital pathology remote consultations, doctors can utilize advanced technology and platforms to overcome geographical limitations and formulate remote diagnostic and treatment plans. This not only increases the utilization of pathology experts but also provides patients with faster and more accurate diagnoses and treatments. Therefore, KFBIO digital pathology remote consultations not only fill the gap in the shortage of pathologists in China but also substantially improve the level of care for cancer patients. #KFBIO #Digitalpathology

🚀 Significant Progress in Precision Medicine for Long COVID & ME/CFS 🧬 PrecisionLife, under the leadership of CEO Dr. Steve Gardner, has recently achieved a major milestone in its ongoing efforts to combat long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The company has returned groundbreaking results from a 1,000-patient clinical trial conducted in partnership with the Metrodora Institute in Salt Lake City. This trial is crucial in validating PrecisionLife's innovative genotypic diagnostic test, which is set to revolutionize the approach to precision medicine. 🔍 Key Developments: PrecisionLife’s advanced combinatorial analytics have led to the identification of 73 novel genes linked to severe long COVID, many of which overlap with ME/CFS and other complex diseases. This discovery provides a deeper understanding of the genetic mechanisms behind these conditions. The company is paving the way for personalized treatment options, including drug repurposing strategies that target specific patient subgroups with mitochondrial, autoimmune, or neurotransmitter dysfunctions. 🌍 Impact and Innovation: These advancements hold the potential to significantly transform the diagnostic and treatment landscape for millions of patients who have long been underserved. By focusing on the underlying causes rather than just the symptoms, PrecisionLife is setting new standards in healthcare. 🔬 Oxford: The Innovation Hub Operating from its headquarters in Oxford, UK, Precision Life is leveraging the area’s strong academic and biotech ecosystem to drive innovation in computational biology and precision medicine. This strategic location supports the company’s global initiatives, including its partnership with the Metrodora Institute. Together, PrecisionLife and Metrodora Institute are rapidly advancing the development of life-changing diagnostics and treatments for patients in need. Stay tuned for more updates as these efforts continue to progress. #PrecisionMedicine #LongCOVID #MECFS #Genomics #HealthcareInnovation #Oxford